Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support...
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022...
Launching the most ambitious and comprehensive health campaign in British Columbia’s historyOne in two British Columbians will face cancer in...
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both...
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering...
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post...
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapyTrial will be conducted...
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
Physician-led network offering complimentary skin cancer screenings across its network of clinics throughout OctoberMAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE)...
HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine...
Appointment strengthens senior leadership team as company advances its first candidate into the clinic and prepares to expand its pipeline...
Reimbursement granted with no restrictions to the labelATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”),...
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with...
Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer DURHAM, N.C.,...
Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in...
Award to support Phase 2 development of IMSA101, a STING agonist, in solid tumor malignanciesDALLAS, Sept. 20, 2022 (GLOBE NEWSWIRE)...
- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,...